Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

Chung Sang Tse; Parambir S Dulai

doi:10.1016/j.gtc.2021.12.005

Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease

Gastroenterol Clin North Am. 2022 Jun;51(2):283-298. doi: 10.1016/j.gtc.2021.12.005. Epub 2022 Apr 22.

Authors

Chung Sang Tse¹, Parambir S Dulai²

Affiliations

¹ Division of Gastroenterology, University of California, San Diego, 9500 Gilman Drive, MC 0956, La Jolla, CA 92093-0956, USA. Electronic address: cstse@ucsd.edu.
² Division of Gastroenterology, University of California, San Diego, 9500 Gilman Drive, MC 0956, La Jolla, CA 92093-0956, USA.

PMID: 35595415
DOI: 10.1016/j.gtc.2021.12.005

Abstract

Over the past 2 decades, there have been incredible advances in the pharmacotherapeutic options for the treatment of patients with moderately to severely active Crohn's disease. Despite the leaps and strides in safety, efficacy, and mechanistic specificity of treatment targets, a significant portion (up to ∼20-50%) of patients have refractory Crohn's disease ± concomitant rheumatologic disease/extraintestinal manifestations for which existing biologic and small molecule therapies are ineffective. In this review, we will explore the available evidence for the use of dual advanced therapies (combination of biologic and/or small molecule therapies) and novel pharmacotherapies in phase 2 to 3 clinical trials.

Keywords: Clinical trials; Combination biologics and small molecules; Dual biologic therapies.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use
Biological Products* / therapeutic use
Crohn Disease* / drug therapy
Humans

Substances

Antibodies, Monoclonal
Biological Products